Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration

Biomaterials

Volumn 25, Issue 4, 2004, Pages 707-714

  Carrascosa, C ^a   Torres Aleman, I ^b   Lopez Lopez, C ^b   Carro, E ^b   Espejo, L ^a   Torrado, S ^a   Torrado, J J ^a,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO CAJAL   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Microsphere; Neurodegeneration; Pharmacokinetic; PLGA IGF I

Indexed keywords

BRAIN; CELLS; EMULSIONS; IMMUNOLOGY; MUSCLE; POLYPEPTIDES; SOLUTIONS;

CELL DEGENERATION;

INSULIN;

MICROSPHERE; POLYGLACTIN; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; CELL DEGENERATION; CIRCULAR DICHROISM; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FEMALE; LIFESPAN; MALE; MICROENCAPSULATION; MOTOR COORDINATION; MOUSE; MUSCLE ATROPHY; NERVE DEGENERATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PURKINJE CELL; RAT; SURVIVAL; WEIGHT GAIN;

ATAXIA;

EID: 0242352380     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(03)00562-3     Document Type: Article

References (34)

1. Thoenen H., Sendtner M. Neurotrophins. from enthusiastic expectations through sobering experiences to rational therapeutic approaches Nat Neurosci. 5(Suppl):2002;1046-1050.
2. Pardridge W.M. Drug and gene delivery to the brain The vascular route. Neuron. 36:2002;555-558.
3. Reinhardt R.R., Bondy C.A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 135:1994;1753-1761.
4. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 12:2002;1390-1397.
5. Fernandez A.M., de la Vega A.G., Torres-Aleman I. Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia. Proc Natl Acad Sci USA. 95:1998;1253-1258.
6. Harris A.G., Kokoris S.P., Ezzat S. Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. J Clin Pharmacol. 35:1995;59-71.
7. Lam X.M., Duenas E.T., Daugherty A.L., Levin N., Cleland J.L. Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Rel. 67:2000;281-292.
8. Meinel L., Illi O.E., Zapf J., Malfanti M., Peter M.H., Gander B. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. J Control Rel. 70:2001;193-202.
9. Singh M., Shirley B., Bajwa K., Samara E., Hora M., O'Hagan D. Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles. J Control Rel. 70:2001;21-28.
10. Amaducci L., Tesco G. Aging as a major risk for degenerative diseases of the central nervous system. Curr Opin Neurol. 7:1994;283-286.
11. Pons S., Torres-Aleman I. Basic fibroblast growth factor modulates insulin-like growth factor-I, its receptor, and its binding proteins in hypothalamic cell cultures. Endocrinology. 131:1992;2271-2278.
12. Carro E., Trejo J.L., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci. 21:2001;5678-5684.
13. Mizuno N., Kato Y., Iwamoto M., Urae A., Amamoto T., Niwa T., Sugiyama Y. Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. Pharm Res. 18:2001;1203-1209.
14. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins. biological actions Endocr Rev. 16:1995;3-34.
15. Woodall S.M., Breier B.H., O'Sullivan U., Gluckman P.D. The effect of the frequency of subcutaneous insulin-like growth factor-1 administration on weight gain in growth hormone deficient mice. Horm Metab Res. 23:1991;581-584.
16. Zhang W., Ghetti B., Yang X.L., Lee W. Alteration of IGF system gene expression during the postnatal development of PCD mice. J Endocrinol. 163:1999;191-198.
17. Hefti F. Neurotrophic factor therapy for nervous system degenerative diseases. J Neurobiol. 25:1994;1418-1435.
18. Higaki K., Matsumoto Y., Fujimoto R., Kurosaki Y., Kimura T. Pharmacokinetics of recombinant human insulin-like growth factor-I in diabetic rats. Drug Metab Dispos. 25:1997;1324-1327.
19. Daughaday W.H., Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 10:1989;68-91.
20. Brower V. IGF in the clinic. Nat Biotechnol. 16:1998;601-602.
21. Torres-Aleman I. Serum growth factors and neuroprotective surveillance. Mol Neurobiol. 21:2000;153-160.
22. Carro E., Nunez A., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci. 20:2000;2926-2933.
23. Grahnen A., Kastrup K., Heinrich U., Gourmelen M., Preece M.A., Vaccarello M.A., Guevara-Aguirre J., Rosenfeld R.G., Sietnieks A. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr. 82(Suppl. 391):1993;9-13.
24. Iioka Y., Tatsumi K., Sugito K., Moriya T., Kuriyama T. Effects of insulin-like growth factor on weight gain in chronic hypoxic rats. J Cardiovasc Pharmacol. 39:2002;636-642.
25. Lai E.C., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Murphy M.F., Natter H.M., Norris F.H., Rudnicki S.A. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I study group. Neurology. 49:1997;1621-1630.
26. Busiguina S., Fernandez A.M., Barrios V., Clark R., Tolbert D.L., Berciano J., Torres-Aleman I. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol Dis. 7:2000;657-665.
27. Schwab S., Spranger M., Krempien S., Hacke W., Bettendorf M. Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury. Stroke. 28:1997;1744-1748.
28. Tham A., Nordberg A., Grissom F.E., Carlsson-Skwirut C., Viitanen M., Sara V.R. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect. 5:1993;165-176.
29. Vanhala R., Turpeinen U., Riikonen R. Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism. Dev Med Child Neurol. 43:2001;614-616.
30. Torrado J., Carrascosa C. Pharmacological characteristics of parenteral IGF-I administration. Curr Pharm Biotechnol. 4:2003;123-140.
31. Torres-Aleman I., Barrios V., Lledo A., Berciano J. The insulin-like growth factor I system in cerebellar degeneration. Ann Neurol. 39:1996;335-342.
32. Poduslo J.F., Curran G.L., Berg C.T. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA. 91:1994;5705-5709.
33. Fransson J., Hallèn D., Florin-Robertsson E. Solvent effects on the solubility of human Insulin-Like growth factor I. Pharm Res. 14:1997;606-612.
34. Souillac P.O., Middaugh C.R., Rytting J.H. Investigation of protein-carbohydrate interactions in the dried state. 2 Diffuse reflectance FTIR studies. Int J Pharm. 235:2002;207-218.